相关临床试验
7
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
14.3%
已完成
4
57.1%
招募中
1
14.3%
终止
1
14.3%
暂无批准数据
- Angitia Biopharmaceuticals has completed enrollment of 379 postmenopausal women with osteoporosis in its Phase 2 ARTEMIS trial evaluating AGA2118, a bispecific antibody targeting sclerostin and DKK1. - The randomized, double-blind, placebo-controlled trial will assess bone mineral density changes at the lumbar spine as its primary endpoint, with topline results expected in 2027. - AGA2118 represents a novel dual-targeting approach designed to prevent compensatory increases in bone metabolism regulators and potentially improve treatment outcomes for the more than 200 million osteoporosis patients worldwide. - The trial includes an open-label extension through 24 months to evaluate both off-treatment effects and continuous treatment benefits of this innovative therapeutic candidate.
- Angitia Biopharmaceuticals' Phase 1/2 study demonstrated that AGA111, a recombinant human bone morphogenetic protein 6, achieved faster radiographic fusion and higher fusion success rates compared to placebo in spinal fusion procedures. - The randomized, double-blind trial enrolled 63 patients with degenerative disc disease requiring Transforaminal Lumbar Interbody Fusion surgery, showing significant improvements in functional outcomes measured by Oswestry Disability Index and pain visual analog scale. - Based on these encouraging results, Angitia has initiated a registrational Phase 3 study of AGA111, which could potentially transform treatment outcomes for the over 446,000 patients undergoing spinal fusion procedures annually in the US and China.
- Angitia Biopharmaceuticals has initiated a Phase 2 clinical trial (ARTEMIS) of AGA2118 for treating postmenopausal osteoporosis. - The ARTEMIS trial is a randomized, double-blind, placebo-controlled study involving approximately 350 postmenopausal women. - AGA2118, a bispecific antibody, targets sclerostin and DKK1 to enhance bone mineral density (BMD) in osteoporosis patients. - The primary endpoint of the study is the percent change from baseline in BMD at the lumbar spine at 12 months.
- Angitia Biopharmaceuticals has dosed the first patient in its Phase 2 ARTEMIS trial evaluating AGA2118 for postmenopausal osteoporosis. - The ARTEMIS trial is a randomized, double-blind, placebo-controlled study assessing the change in bone mineral density at the lumbar spine over 12 months. - AGA2118 is a bispecific antibody targeting sclerostin and DKK1, aiming to enhance bone mineral density gains by preventing compensatory increases of either agent. - The global osteoporosis epidemic affects over 200 million people, highlighting the unmet need for new therapies with improved efficacy and safety profiles.
